

Dr Elisabeth Erlacher-Vindel

Head of Antimicrobial Resistance and
Veterinary Products Department

Global Tripartite activities on Antimicrobial Resistance (AMR)

Kuala Lumpur, Malaysia

14-16 January 2020



Tripartite global activities: recent developments



- ▶ Memorandum of Understanding 2018
- ▶ The Tripartite workplan on AMR
- ▶ Multi-Partner Trust Fund
- ▶ Monitoring and Evaluation of the Global Action Plan on Antimicrobial Resistance

http://www.oie.int/fileadmin/Home/eng/Media_Center/docs/pdf/onehealthportal/MoU_Tripartite_Signature_May_30_2018.pdf

Tripartite activities: recent developments

UN Inter-agency coordination Group (IACG)

- Set up by the UN Secretary General as per request of the 71st UN General Assembly
- OIE represented in the coordination group, and in the Tripartite IACG secretariat
- Mandate: practical guidance on sustained global action on AMR

→ IACG report provided to the UNSG in April 2019

14 recommendations,
including on global governance



NO TIME TO WAIT:
SECURING THE FUTURE FROM
DRUG-RESISTANT INFECTIONS

REPORT TO THE SECRETARY-GENERAL
OF THE UNITED NATIONS

29 APRIL 2019

<http://www.oie.int/en/for-the-media/press-releases/detail/article/new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis/>

IACG recommendations on governance

- E1** The IACG **requests the Tripartite** together with UNEP, other UN agencies and the World Bank, in the context of UN reform, to further strengthen joint One Health action, based on target-setting, country priorities and needs, by enhancing their organizational capacity and providing adequate and sustainable core funding for AMR-related activities.
- E2** The IACG recommends the urgent establishment of a **One Health Global Leadership Group on Antimicrobial Resistance**, supported by a **Joint Secretariat** managed by the Tripartite agencies.
- E3** The IACG requests the Secretary-General, in close collaboration with the Tripartite agencies , UNEP and other international organizations, to convene an **Independent Panel on Evidence for Action against Antimicrobial Resistance** in a One Health context to monitor and provide Member States with regular reports on the science and evidence related to antimicrobial resistance, its impacts and future risks, and to recommend options for adaptation and mitigation.

IACG follow-up

Global Leaders Group

- Public discussion
- Finalization of ToRs, UNSG appoints

Independent Panel

- Advisory Group to help setting up
- Public discussion will follow

Stakeholder Platform

- At a later stage

Tripartite activities: recent developments

UNSG report to the 73rd UN General Assembly

Drafted by the Tripartite and handed to the UN Secretary General in April 2019

- ▶ Update on implementation of UN declaration A-71/3
 - Including support to Members' capacities to effectively address antimicrobial resistance by collectively elaborating and implementing multisectoral One Health National Action Plans (NAPs)
- ▶ Linking to the IACG recommendations
- ▶ Conclusion and ways forward
- ▶ <https://undocs.org/pdf?symbol=en/A/73/869>

Establishment of the Joint Tripartite Secretariat

United Nations

A/73/869



General Assembly

Distr.: General
10 May 2019

Original: English

Seventy-third session

Agenda item 129

Global health and foreign policy

**Follow-up to the political declaration of the high-level
meeting of the General Assembly on
antimicrobial resistance**

Report of the Secretary-General



June 2019

Tripartite Joint Secretariat on Antimicrobial Resistance

Purpose: Lead and coordinate the global response to AMR in close collaboration with the UN system and other organizations. The Tripartite Joint Secretariat consolidates cooperation between WHO, FAO and OIE, drawing on their core mandates and comparative advantages to address needs of the global response across the One Health spectrum.

Hosting arrangement

Hosted by WHO with a critical mass of staff, along with dedicated liaison officers working in FAO and OIE


Governance arrangement

- The Executive Committee
- The Senior Management Group
- The Tripartite Joint Secretariat team

Key functions

- Global promotion, advocacy and political engagement
- Support global governance structures on AMR
- Coordinate interagency engagement and partnership
- Coordinate and monitor Tripartite workplans on AMR
- Map gaps and opportunities
- Support the functioning of the AMR Multi-Partner Trust Fund

Tripartite Workplan 2019-2020: 5 focus areas for multisectoral collaboration



Food and Agriculture
Organization of the
United Nations



World Health
Organization

Tripartite Country Self Assessment Survey (TrACSS)

- Tracking countries progress *on AMR* objectives - Self Assessment
- Multi-sectoral
- Data for national and global analysis (baselines)
- Contributed to the Secretary Generals report to the United Nations General Assembly (2019)
<https://undocs.org/en/A/73/869>
- The Self Assessment survey now - fourth round can be found at:
<http://www.who.int/antimicrobial-resistance/global-action-plan/database/en/>




5.1 Country progress with development of a national action plan on AMR*

o	A	No national AMR action plan.
o	B	National AMR action plan under development.
o	C	National AMR action plan developed.
o	D	National AMR action plan approved by government that reflects Global Action Plan objectives, with an operational plan and monitoring arrangements.
o	E	National AMR action plan has funding sources identified, is being implemented and has relevant sectors involved with a defined monitoring and evaluation process in place.

Tripartite Annual Self-Assessment Survey


Progress made in the development of national action plans




Source: Reporting by WHO regional offices and on the basis of the 2018/19 country self-assessment survey on antimicrobial resistance of the Tripartite Organizations.

Tripartite Coordination and the GAP M&E Framework


- Practical, data-driven system to determine success of the GAP delivery
- AMR M&E framework provides a recommended list of indicators to be measured at National or global level (including OIE Global AMU Database, PVS, TrACSS...)
- Can be used to inform decision making
- AMR M&E Framework with standardised indicators is being piloted by the Tripartite




Tripartite Multi-Partner Trust Fund




Food and Agriculture
Organization of the
United Nations



WORLD ORGANISATION
FOR ANIMAL HEALTH




World Health
Organization



©World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO) and World Organisation for Animal Health (OIE), 2019

Antimicrobial Resistance Multi-Partner Trust Fund

Combating the rising global threat of AMR through a One Health Approach



Dr Elisabeth Erlacher-Vindel

Head of Antimicrobial Resistance and
Veterinary Products Department

Antimicrobial Resistance (AMR): current and future OIE activities


Kuala Lumpur, Malaysia
14-16 January 2020



Resolution No.14 adopted by the OIE General Assembly in May 2019

To maintain a **global perspective** and foresight on antimicrobial resistance regarding animal health and the interface with human health, food production and the environment.

To identify risks and risk management options associated with antimicrobial resistance through development and maintenance of OIE International Standards in the *Terrestrial* and *Aquatic Codes* and *Manuals*.



OIE Working Group on Antimicrobial Resistance

To support the
implementation of the
OIE Global Strategy
on AMR
and the organization's
capacity to respond to
global challenges



OIE Working Group on AMR

Members

- Tomoko Ishibashi - Chair (Japan)
- Gérard Moulin (France)
- Donald Prater (USA)
- Moritz van Vuuren (South Africa)
- Fajer Al Salloom (Bahrain)
- Stephen Page (Australia)
- Barbara Freischem (European Medicines Agency)

Terms of Reference

Assist the OIE Director General, in the implementation of the OIE Strategy on Antimicrobial Resistance and the Prudent use of Antimicrobials, in particular the:

- OIE collection of data intended for use of antimicrobial agents and Tripartite Integrated Surveillance System on AMR;
- refinement of the OIE List of Antimicrobial Agents of Veterinary Importance and follow up of its recommendations;
- capacity development activities in OIE Member Countries (PVS Pathway, OIE Focal Point training, and e-learning platforms)
- communications activities to raise awareness and create behavioural change;
- establishment of an information system on falsified and substandard drugs;

Terms of Reference

- support the OIE in its Tripartite activities following the Global Action Plan and its role within the **future secretariat in relation to the global governance mechanisms that is to be established.**
- support the activities of OIE Collaborating Centres and encourage the establishment of an **effective network of expertise** in support of the OIE and its Member Countries. Countries.
- advise the OIE in its interactions and collaborations to **achieve strong coordination on antimicrobial resistance** within this community of interest.

OIE Working Group on AMR

- ➔ **First meeting: October 2019**
Second meeting: March 2019

Report WG AMR • Rapport WG AMR • Informe WG AMR • Oct2019

zmakoni@mcaz.co.zw

c Elisabeth Erlacher-Vindel; Delfy Gochez; Morgan Jeannin; Monique Eloit; Matthew Stone

To OIE Focal Points on Veterinary Products	Aux Points focaux de l'OIE pour les produits vétérinaires	Para las Puntos focales de la OIE por productos veterinarios
FOR YOUR INFORMATION	POUR VOTRE INFORMATION	PARA SU INFORMACIÓN
To Delegates of OIE Member Countries	Aux Délégués des Pays Membres de l'OIE	A los Delegados de los Países Miembros de la OIE
<p>Dear Delegates</p> <p>Please find attached the provisional version of the:</p> <ul style="list-style-type: none">– Report of the meeting of the OIE Working Group on Antimicrobial Resistance, 1-3 October 2019. <p>This report are also available on the website of Delegates and the OIE Website.</p> <p>With best regards,</p> <p>Monique Eloit OIE Director General</p>	<p>Mesdames et Messieurs les Délégué(e)s</p> <p>Veuillez trouver ci-jointes la version provisoire du :</p> <ul style="list-style-type: none">– Rapport de la réunion du Groupe de travail de l'OIE sur la résistance aux agents antimicrobiens, 1-3 octobre 2019 <p>Ce rapport est également disponible sur le site des Délégués et sur le site de l'OIE.</p> <p>Je vous prie d'agréer, Cher(e) Délégué(e), mes salutations distinguées.</p> <p>Monique Eloit Directrice générale de l'OIE</p>	<p>Estimados/as Delegados/as:</p> <p>Sírvase encontrar adjunta la versión provisional del:</p> <ul style="list-style-type: none">– Informe de la reunión del Grupo de Trabajo de la OIE sobre la resistencia a los agentes antimicrobianos, 1-3 de octubre de 2019 <p>Este informe también está disponible en el sitio web de Delegados y en el sitio web de la OIE.</p> <p>Reciba mis más cordiales saludos.</p> <p>Monique Eloit Directora General de la OIE</p>
(Click in the link) • (Cliquez sur lien) • (haga clic en el vínculo)		

<https://www.oie.int/en/standard-setting/specialists-commissions-working-ad-hoc-groups/working-groups-reports/working-group-on-amr/the-group-reports/#c42477>

OIE Global database on antimicrobial agents intended for use in animals

In the framework of the Global Action Plan on AMR, the OIE, under the Tripartite collaboration, has taken the lead to build a global database on antimicrobial agents intended for use in animals.

The database is designed to:

1. • Monitor the type and use of antimicrobial products
2. • Measure trends over time
3. • Trace circulation and use patterns globally
4. • Evaluate the quality and authenticity of antimicrobial products in use

OIE Global database on antimicrobial agents intended for use in animals

1st Round:

- Oct 2015 – May 2016
- 1st Report - published in Dec 2016
- Data ranging from 2010 - 2015

2nd Round:


- Oct 2016 – May 2017
- 2nd Report - published in Dec 2017
- Data ranging from 2013 - 2016

3rd Round:

- Oct 2017 – May 2018
- 3rd Report - published on 14 Feb 2019
- Data ranging from 2015 - 2017

4th Round:

- Sept 2018 – May 2019



Data collection on AMU in animals

- Focus on sales of antimicrobial agents destined for use in animals as an indicator of actual use and for those agents listed in the OIE 'List of antimicrobial agents of veterinary importance'
- The [OIE template \(Microsoft Excel file\)](#) - 4 worksheets

*** This sheet of the OIE template should be completed by all OIE Member Countries ***
Please refer to the Guidance document for further instructions.

A. Contact Person for Antimicrobial Agents Use Data Collection

1	Title	<free text field>
2	Name (First name, SURNAME)	<free text field>
3	Role with respect to the OIE	<input type="checkbox"/> OIE Delegate <input type="checkbox"/> OIE Focal Point for Veterinary Products <input type="checkbox"/> Other
4	Organisation	<free text field>
5	Organisation's Address	<free text field>
6	Country	<free text field>
7	Phone Number	<free text field>
8	Email Address	<free text field>

B. General Information

Questions 9 to 14 are related to the current situation in your country. Responses should not be linked to the year of antimicrobial quantities reported.

9	Are data on the amount of antimicrobial agents intended for use in animals available?	<input type="checkbox"/> Amounts available - Yes <input type="checkbox"/> Amounts available - No
10	Please indicate why the data are not available at this time in your country, if the answer to Question 9 is 'No'	<free text field>

Baseline Information Reporting Option 1 Reporting Option 2 Reporting Option 3

OIE template for the collection of data on antimicrobial agents intended for use in animals
Reporting option 1 - Overall amount sold for/used in animals by antimicrobial class; with the possibility to separate by type of use

Antimicrobial Class	Overall Amount: Veterinary Medical Use + Growth Promotion	Amount: Veterinary Medical Use (including prevention of clinical signs)	Amount: Growth Promotion
	All animal species (kg)	All animal species (kg)	All animal species (kg)
Aminoglycosides	0		
Amphenicols	0		
Arsenicals	0		
Cephalosporins (all generations)	0	0	0
1-2 gen. cephalosporins	0		
3-4 gen cephalosporins	0		
Fluoroquinolones	0		
Glycopeptides	0		
Glycophospholipids	0		
Incosamides	0		
Macrolides	0		
Nitrofurans	0		
Orthosomycins	0		
Other quinolones	0		

Baseline Information Reporting Option 1 Reporting Option 2 Reporting Option 3

OIE template for the collection of data on antimicrobial agents intended for use in animals
Reporting option 2 - Overall amount sold for/used in animals by antimicrobial class; with the possibility to separate by type of use and species group

Antimicrobial Class	Overall Amount: Veterinary Medical Use + Growth Promotion	Amount: Veterinary Medical Use (including prevention of clinical signs)					Amount: Growth Promotion
	All animal species (kg)	All animal species (kg)	Companion animals (kg)	All food-producing animals (terrestrial & aquatic) (kg)	Terrestrial food-producing animals (kg)	Aquatic food-producing animals (kg)	All food-producing animals (terrestrial & aquatic) (kg)
Aminoglycosides	0	0	0	0	0	0	0
Amphenicols	0	0	0	0	0	0	0
Arsenicals	0	0	0	0	0	0	0
Cephalosporins (all generations)	0	0	0	0	0	0	0
1-2 gen. cephalosporins	0	0	0	0	0	0	0
3-4 gen cephalosporins	0	0	0	0	0	0	0
Fluoroquinolones	0	0	0	0	0	0	0
Glycopeptides	0	0	0	0	0	0	0
Glycophospholipids	0	0	0	0	0	0	0
Incosamides	0	0	0	0	0	0	0
Macrolides	0	0	0	0	0	0	0
Nitrofurans	0	0	0	0	0	0	0
Orthosomycins	0	0	0	0	0	0	0
Other quinolones	0	0	0	0	0	0	0
Penicillins	0	0	0	0	0	0	0
Pleuromulins	0	0	0	0	0	0	0
Polypeptides	0	0	0	0	0	0	0

Baseline Information Reporting Option 1 Reporting Option 2 Reporting Option 3

OIE template for the collection of data on antimicrobial agents intended for use in animals

Reporting option 3 - Overall amount sold for/used in animals by antimicrobial class; with the possibility to separate by type of use, species

Antimicrobial Class	Overall Amount: Veterinary Medical Use + Growth Promotion	Amount: Veterinary Medical Use (including prevention of clinical signs)												Amount: Growth Promotion				
	All animal species	All animal species				Companion animals			All food-producing animals (terrestrial and aquatic)			Terrestrial food-producing animals			Aquatic food-producing animals (terrestrial and aquatic)			All food-producing animals (terrestrial and aquatic)
		All routes (kg)	Oral route (kg)	Injection route (kg)	Other routes (kg)	Oral route (kg)	Injection route (kg)	Other routes (kg)	Oral route (kg)	Injection route (kg)	Other routes (kg)	Oral route (kg)	Injection route (kg)	Other routes (kg)	Oral route (kg)	Injection route (kg)	Other routes (kg)	
Aminoglycosides	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Amphenicols	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Arsenicals	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Cephalosporins (all generations)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
1-2 gen. cephalosporins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3-4 gen cephalosporins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Fluoroquinolones	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Glycopeptides	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Glycophospholipids	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Incosamides	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Macrolides	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Nitrofurans	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Orthosomycins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Other quinolones	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Penicillins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Pleuromulins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Polypeptides	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Streptogramins	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Tetracyclines (excluding chlortetracycline)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Tetracyclines	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Trimethoprim	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Vancomycin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Aggregated other data	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Baseline Information

Reporting Option 1

Reporting Option 2


Reporting Option 3

+

-

Reporting Options


The sections of the OIE Template named 'Reporting Options' 1, 2 and 3, collect the quantities of antimicrobial agents intended for use in animals.



* Type of use: veterinary medical use or growth promotion

** For the purposes of the OIE database, animal groups means: 'terrestrial food-producing animals', 'aquatic food-producing animals' or 'Companion animals'

Participation Progress



Interaction with the Countries (4th Round)

Administrative validation



Delegate in copy



Right form of the questionnaire

Administrative validation

Technical validation

Submitting the questionnaire

Technical validation



All fields answered



Coherence on the answers



Comparing country data over time



Calculations of kg of active ingredient

616 emails exchanged with the countries through


antimicrobialuse@oie.int

- 213 with Africa
- 134 with the Americas
- 98 with Asia and the Pacific
- 146 with Europe
- 25 with Middle East


Need for an automated system

Exchange with Countries


- Validation of the data (emails – phone calls)
- Around 80% of the countries changed their original report after the clarifications:
 - Data sources
 - Quantities
 - Antimicrobial growth promoters
 - Reporting Option
 - Data Coverage




Comparison of the Proportion of Countries Submitting Questionnaires by OIE Region




Contact Person Profile of 153 Member Countries that Submitted the OIE Template in the 3rd Round (2017)




- Delegate
- Focal Point for Veterinary Products
- Other national competent authority




Antimicrobial Agents Used for Growth Promotion in Animals in 31 Countries, Third Round (2017)



Comparison of Data Types Reported in the OIE Data Collection




Validated Data Sources Selected by 94 Countries Reporting Quantitative Data from 2015 to 2017, Third Round



Exchanges with Countries:
-582 emails
-20 phone calls

Proportion of Antimicrobial Quantities (by Antimicrobial Class) Reported for Use in Animals During the Third Round by 116 Countries from 2015 to 2017




Work on the Animal Biomass (Denominator)




- Each country has **variability in animal population numbers, production cycles** and **average weights**.
 - Animal biomass is calculated using country-level animal population data by species, data-derived estimates of their average weights by sub-region and country, and average reproductive rates of short-lived species (cycle factor).
- ➡ kilogram animal biomass for use as a denominator in analysis of antimicrobial use data (mg/kg)
- Allows for comparisons of trends between OIE Regions and over time.

Species Composition of Animal Biomass for 91 Countries Included in 2015 Quantitative Data Analysis



Quantities of Antimicrobial Agents Intended for Use in Animals as Reported for 2015:

$\frac{\text{Antimicrobial agents (mg)}}{\text{Animal biomass (kg)}}$



Future Development (AMU Database System)




Country Data Ownership

- Specific trend analysis
- Raised awareness
- Increased transparency



Less burden for data entry

- Automatic calculations
- Data quality check
- Detailed data analysis



Refinement of Information

- Species level data
- Farm level data
- Connection with other data sources:
 - ✓ OIE-WAHIS (World Animal Health Information System)
 - ✓ TISSA (Tripartite Integrated System for Surveillance on AMR and Antimicrobial Use)
 - ✓ PVS (Performance of Veterinary Services)

Regional Trainings of OIE Focal Points on Veterinary Products /AMR

Trainings in 2019/20 (6th cycle), Focal Point network started in 2009

■ AMERICAS

- 26-27 September 2019. Montego Bay, Jamaica

■ AFRICA

- 9 -11 July 2019. Addis Ababa, Ethiopia
- 9 -11 October 2019. Lomé, Togo
- 29-31 October 2019. Mombasa, Kenya

■ ASIA

- **January 2020 Malaysia**

■ MIDDLE EAST

- Spring 2020

■ EUROPE

- Second half of 2020





WE NEED YOU

TO HANDLE
ANTIMICROBIALS
WITH CARE

Fight
#AntiMicrobialResistance

- Misuse and overuse of antimicrobials increase resistance risk, endangering both animal and human health and welfare.
- But you can help. By acting prudently when using antimicrobials, you can preserve their efficacy for our future.

WE NEED YOU

Oie WORLD ORGANISATION FOR ANIMAL HEALTH
Protecting animals, preserving our future

 Funded by
UK Government



WORLD ORGANISATION FOR ANIMAL HEALTH
Protecting animals, preserving our future

Thank you for your attention

12, rue de Prony, 75017 Paris, France

www.oie.int

media@oie.int - oie@oie.int

